April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Evaluation of the neuroprotective effects of trabodenoson in a model of acute ocular hypertension
Author Affiliations & Notes
  • alireza ghaffarieh
    Ophthalmology, University of Wisconsin Madison, Madison, WI
  • Christopher J Lieven
    Ophthalmology, University of Wisconsin Madison, Madison, WI
  • Leonard A Levin
    Ophthalmology, University of Wisconsin Madison, Madison, WI
    Ophthalmology, McGill University, Montreal, QC, Canada
  • William K McVicar
    Inotek Pharmaceuticals, Lexington, MA
  • Footnotes
    Commercial Relationships alireza ghaffarieh, Inotek (F); Christopher Lieven, Inotek (F); Leonard A Levin, Inotek (F); William McVicar, Inotek Pharmaceuticals (E), Inotek Pharmaceuticals (I), Inotek Pharmaceuticals (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2427. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      alireza ghaffarieh, Christopher J Lieven, Leonard A Levin, William K McVicar; Evaluation of the neuroprotective effects of trabodenoson in a model of acute ocular hypertension. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2427.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Trabodenoson has been shown to lower intraocular pressure in humans with ocular hypertension or open-angle glaucoma (JS Myers, ARVO 2013 #2621). Glaucomatous vision loss is due to optic nerve neuropathy with consequent loss of retinal ganglion cells (RGCs). Adenosine is known to be neuroprotective in the brain via A1 receptor activation.1 In animals, adenosine has also been shown to protect the retina against ischemia.2 Trabodenoson, an adenosine mimetic selective for the A1 receptor, was investigated for its potential to protect RGCs in rats subjected to acute ocular hypertension.

Methods: Male Long Evans rats, 6 to 8 weeks old, were anesthetized and topical anesthetic applied to the cornea of the right eye, followed by two drops, 5 minutes apart, of 2.5% trabodenoson, 0.2% brimonidine, or vehicle. The anterior chamber was cannulated with a 30G needle attached to a saline reservoir and the pressure raised to 110 mmHg for 60 minutes. Animals were sacrificed 7 days later and the eyes and optic nerves were fixed and embedded in JB-4 for sagittal sectioning. Toluidine blue stained sections were imaged and the thickness of retinal layers were measured at each of 5 random locations. Images were captured and measurements performed using cellSens Dimension software on an Olympus BX61 microscope. Distances and counts in acutely hypertensive eyes were normalized to the mean of the naïve contralateral eye and compared by Student’s t-test.

Results: Vehicle-treated animals (n = 10) showed a decrease in retinal thickness, most prominently in the inner retina (72 ± 5%, 66 ± 4%, and 85 ± 4% of paired naïve eyes in the ganglion cell, inner plexiform, and inner nuclear layers, respectively). Topical trabodenoson treatment (n = 10) significantly ameliorated the thinning in all three of these layers (100 ± 5%, p <0.001; 85 ± 3%, p < 0.001; and 96 ± 3%, p = 0.04, respectively). Brimonidine treatment (n = 10) was neuroprotective in the ganglion and inner plexiform layers only (94 ± 5%, p = 0.001; 79 ± 3%; p = 0.01: 90 ± 3%; p = 0.31).

Conclusions: Trabodenoson preserves inner retinal neurons in a rat model of acute optic hypertension. 1. Cunha, RA, Purinergic Signal. 2005; 1(2): 111-134; 2. Larsen AK, et al, Invest. Ophthalmol. Vis. Sci. 1996; 37:2603-2611.

Keywords: 615 neuroprotection • 568 intraocular pressure • 531 ganglion cells  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.